Clinical Trials
11 articles
Novo Nordisk security breach exposes patient data in cyberattack
Patient data, including sensitive medical histories from some of Novo Nordisk's clinical trials, was compromised in a recent cybersecurity breach.
Long Covid Patients Face Stalemate in Biomedical Research
For 14 potential long COVID interventions, evidence certainty was mostly low to very low, leaving millions without clear guidance.
Pfizer's obesity drug shows potential for monthly dosing
Mid-stage study data reveals Pfizer's experimental obesity drug, berobenatide, could achieve significant weight loss with a groundbreaking monthly dosing schedule, a stark contrast to current weekly o
Retatrutide's Triple Hormone Action Aims to Revolutionize Obesity Treatment
Patients on the highest dose of retatrutide lost an average of 28% of their body weight over 80 weeks in the latest study, a result mirroring bariatric surgery, according to the South Florida Reporter
AI Drug Development Surges: In Silico Trials Market Grows Dramatically
Biotech firm Insilico Medicine used artificial intelligence to discover a novel drug candidate for idiopathic pulmonary fibrosis (IPF) and advance it to Phase I clinical trials in under 30 months, acc
Phage therapy adoption hurdles: Regulatory and clinical challenges.
By 2050, antimicrobial resistance (AMR) is projected to cause 10 million deaths worldwide annually.
BioNTech, Pfizer Share Bispecifics Data at ASCO
BioNTech's BNT142 achieved 7 RECIST 1.
Bristol Myers Squibb shows strong multiple myeloma data
In a significant development for multiple myeloma patients, Bristol Myers Squibb's mezigdomide triplet demonstrated a median progression-free survival of 18 months, more than doubling the 8.
Bepirovirsen data shows functional cure in 19% of hepatitis B patients
An experimental hepatitis B treatment achieved a 'functional cure' in nearly 1 in 5 patients during its pivotal Phase 3 studies, a significant stride against a chronic viral infection that afflicts mi
New drug Bepirovirsen functionally cures hepatitis B in some patients
In two late-stage clinical trials, GSK's experimental drug Bepirovirsen achieved a functional cure for 19% of patients with chronic hepatitis B, a disease that has long resisted effective treatment.
Merck Halts Parkinson's Drug Program After Phase 3 Setback
Merck's Parkinson's drug, preladenant, was discontinued in 2026 after Phase 3 trials showed it was no more effective than a placebo.